These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31033521)

  • 1. Beyond the Label: Ensuring That Drug Benefits Outweigh Risks in the Food and Drug Administration's Risk Evaluation and Mitigation Strategy Program.
    Epstein MS; Shah ED; Deepak P; Kushnir VM
    Am J Gastroenterol; 2019 Jul; 114(7):1017-1019. PubMed ID: 31033521
    [No Abstract]   [Full Text] [Related]  

  • 2. The US Food and Drug Administration's use of regular approval for cancer drugs based on single-arm studies: implications for subsequent evidence generation.
    DeLoughery EP; Prasad V
    Ann Oncol; 2018 Mar; 29(3):527-529. PubMed ID: 29346605
    [No Abstract]   [Full Text] [Related]  

  • 3. Flight 483 now boarding.
    Czap A
    Altern Med Rev; 2010 Sep; 15(3):183-5. PubMed ID: 21155619
    [No Abstract]   [Full Text] [Related]  

  • 4. What makes consumers think dietary supplements are safe and effective? The role of disclaimers and FDA approval.
    Dodge T; Kaufman A
    Health Psychol; 2007 Jul; 26(4):513-7. PubMed ID: 17605572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the approved Risk Evaluation and Mitigation Strategy programs for New Drug Applications and Biologics Licensing Applications.
    Johnson NA; Priefer R
    Regul Toxicol Pharmacol; 2019 Feb; 101():53-56. PubMed ID: 30473489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Food and Drug Administration's import alerts appear to be "misbranded".
    Humphrey CM
    Food Drug Law J; 2003; 58(4):595-612. PubMed ID: 15027452
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of Risk Evaluation and Mitigation Strategies by the US Food and Drug Administration, 2008-2019.
    Guadamuz JS; Qato DM; Alexander GC
    JAMA; 2020 Jul; 324(3):299-301. PubMed ID: 32692379
    [No Abstract]   [Full Text] [Related]  

  • 8. Two-stage drug approval would reduce the risks.
    Frantz JA
    Nature; 2005 May; 435(7039):143. PubMed ID: 15889063
    [No Abstract]   [Full Text] [Related]  

  • 9. Off-label drugs: question your doctor.
    Consum Rep; 2007 Jun; 72(6):47. PubMed ID: 17632948
    [No Abstract]   [Full Text] [Related]  

  • 10. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry.
    Karst KR
    Am Univ Law Rev; 2000; 49():739-72. PubMed ID: 11067732
    [No Abstract]   [Full Text] [Related]  

  • 11. "Fast tracking" drug approvals: is consumer safety being compromised?
    Jacobsen K
    QRC Advis; 2000 Jun; 16(8):5-9. PubMed ID: 10977137
    [No Abstract]   [Full Text] [Related]  

  • 12. Pros and cons of off-label promotion investigations and prosecutions.
    Loucks MK
    Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
    [No Abstract]   [Full Text] [Related]  

  • 13. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked?
    Shulman SR; Brown JS
    Food Drug Law J; 1995; 50(4):503-31. PubMed ID: 10343017
    [No Abstract]   [Full Text] [Related]  

  • 14. Ensuring that accelerated approvals benefit patients.
    The Lancet Haematology
    Lancet Haematol; 2021 Sep; 8(9):e613. PubMed ID: 34450093
    [No Abstract]   [Full Text] [Related]  

  • 15. Off-label uses of drugs and medical devices: should the FDA crack down?
    Margolis RE
    Healthspan; 1993 Jan; 10(1):18-9. PubMed ID: 10124289
    [No Abstract]   [Full Text] [Related]  

  • 16. The FDA's generic-drug approval process: similarities to and differences from brand-name drugs.
    Kefalas CH; Ciociola AA
    Am J Gastroenterol; 2011 Jun; 106(6):1018-21. PubMed ID: 21637264
    [No Abstract]   [Full Text] [Related]  

  • 17. The Food and Drug Administration's paternalism.
    Somberg JC
    Am J Ther; 2010; 17(6):533-4. PubMed ID: 21060255
    [No Abstract]   [Full Text] [Related]  

  • 18. An introduction to risk evaluation and mitigation strategies.
    Dohm J; Ji M
    Contraception; 2021 Jul; 104(1):4-7. PubMed ID: 33905706
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluating the safety of diabetes drugs: perspective of a Food and Drug Administration insider.
    Misbin RI
    Diabetes Care; 2005 Oct; 28(10):2573-6. PubMed ID: 16186303
    [No Abstract]   [Full Text] [Related]  

  • 20. Inside the black box: current policies and concerns with the United States Food and Drug Administration's highest drug safety warning system.
    Halloran K; Barash PG
    Curr Opin Anaesthesiol; 2010 Jun; 23(3):423-7. PubMed ID: 20446348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.